Abstract C110: miR195 - A potential therapeutic molecule for breast cancer: Present and future

Abstract

Abstract Breast cancer is the leading cause of death in women worldwide (Globocan 2020). Surgery, chemotherapy as well as radiation therapy are the commonly used modes of treatment and the treatment depends on the tumor type. Patients develop resistance and demonstrate poor prognosis after prolonged treatment. Hence there’s is always a need for new diagnostics and therapeutics. miRNAs are 18-22 nucleotides small RNAs known to play a role in development and disease. Deregulation of miRNAs in diseased conditions can be harnessed as potential therapeutics by miRNA mimics or miRNA inhibition by antimiRs. Till date, several miRNA-targeted therapeutics have reached clinical development. Our laboratory has shown that miR-195 not only down regulates anti-apoptotic protein bcl-2 but also key genes of lipid metabolism (FASN, HMGCR) which are upregulated in breast cancer. The altered calcium signaling is deleterious to cells and is also known to be associated with different hallmarks of cancer. We recently observed that miR-195 perturbs calcium homeostasis in breast cancer cells by down-regulating a major calcium efflux pump present on the plasma membrane. Experimental validation has been performed in breast cancer cells and spheroids using western blotting, qRT-PCR, dual luciferase assay, calcium measurements using flow cytometry and immunofluorescence. MiR-195 alters calcium homeostasis leading to ER stress and autophagy in breast cancer. The current work describes recent advances in our understanding of miRNA-195 in breast cancer. Citation Format: Paresh Purohit, Neeru Saini. miR195 - A potential therapeutic molecule for breast cancer: Present and future [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr C110.